LianBio

LianBio (OTC: LIANY) is a cross-border biopharmaceutical company incorporated in 2019 and headquartered in Princeton, New Jersey, focused on developing and commercializing clinically validated medicines for patients in China and other major Asian markets across therapeutic areas including cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications. The company built its pipeline by securing exclusive licensing rights to late-stage drug candidates from Western biotechnology firms, with key assets including mavacamten for hypertrophic cardiomyopathy, NBTXR3 for solid tumors in partnership with Nanobiotix S.A., and TP-03 for Demodex blepharitis in partnership with Tarsus Pharmaceuticals. Founded and seeded by Perceptive Advisors, LianBio went public in November 2021; however, the company has since announced a wind-down of its operations and is currently pursuing the sale of its remaining pipeline assets. As of the latest available data, LianBio carries a market capitalization of approximately $12.1 million, reflecting the significant challenges faced during its operational restructuring.